NASDAQ: AKRO
Akero Therapeutics Inc Stock Ownership - Who owns Akero Therapeutics?

Insider buying vs selling

Have Akero Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Andrew ChengPresident and CEO2025-07-1015,314$51.73
$792.22kSell
Andrew ChengPresident and CEO2025-07-1014,686$50.57
$742.67kSell
Timothy RolphChief Scientific Officer2025-07-0712,500$21.09
$263.63kBuy
Timothy RolphChief Scientific Officer2025-07-0741$52.62
$2.16kSell
Timothy RolphChief Scientific Officer2025-07-0710,634$50.93
$541.61kSell
Timothy RolphChief Scientific Officer2025-07-071,825$52.00
$94.89kSell
Patrick LamySenior VP Commercial Strategy2025-07-012,000$52.88
$105.76kSell
William Richard WhiteChief Financial Officer2025-06-30890$23.87
$21.24kBuy
Patrick LamySenior VP Commercial Strategy2025-06-30193$23.87
$4.61kBuy
Timothy RolphChief Scientific Officer2025-06-30890$23.87
$21.24kBuy

1 of 23

AKRO insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when AKRO insiders and whales buy or sell their stock.

AKRO Shareholders

What type of owners hold Akero Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Rtw Investments LP9.31%7,419,340$385.81MInstitution
Janus Henderson Group PLC8.87%7,068,648$367.57MInstitution
Versant Venture Capital VI LP8.47%6,749,283$350.96MInsider
Blackrock Inc7.85%6,255,024$325.26MInstitution
Wellington Management Group LLP7.45%5,936,240$308.68MInstitution
Apple Tree Partners IV LP7.31%5,830,203$303.17MInsider
General Atlantic LP6.57%5,233,989$272.17MInstitution
Price T Rowe Associates Inc6.04%4,817,091$250.49MInstitution
Vanguard Group Inc5.31%4,230,644$219.99MInstitution
Aaron Royston4.96%3,954,858$205.65MInsider

1 of 3

AKRO vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
AKRO73.69%26.31%Net BuyingNet Selling
SLNO31.69%68.31%Net SellingNet Selling
MTSR43.57%56.43%Net Buying
KRYS78.38%21.62%Net SellingNet Selling
PTCT84.70%15.30%Net SellingNet Selling

Akero Therapeutics Stock Ownership FAQ

Who owns Akero Therapeutics?

Akero Therapeutics (NASDAQ: AKRO) is owned by 108.43% institutional shareholders, 38.72% Akero Therapeutics insiders, and 0.00% retail investors. Versant Venture Capital VI LP is the largest individual Akero Therapeutics shareholder, owning 6.75M shares representing 8.47% of the company. Versant Venture Capital VI LP's Akero Therapeutics shares are currently valued at $348.06M.

If you're new to stock investing, here's how to buy Akero Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.